Objective: To compare the efficacy and safety of cilnidipine and losartan in hypertensive patients with type 2 diabetes mellitus (type 2 DM). Materials and Methods: In this observational, prospective study, hypertensive patients with type 2 DM receiving cilnidipine and losartan were included. Demographic details, clinical history, serum potassium, and urinary albumin were recorded in a case record form. Patients were followed up every monthly up to 24 weeks and observed for clinical and laboratory parameters and adverse drug reactions (ADRs). Data were analyzed using paired t-test, unpaired t-test, and Fisher's exact test. Results: Out of 114 patients, 59 received cilnidipine and 55 patients received losartan. By 24 weeks, both cilnidipine and losartan significantly (P < 0.01) improved mean blood pressure and urinary albumin. However, mean decrease in urinary albumin was significant (P < 0.005) with cilnidipine (20.6 ± 20.4 mg/day) as compared to losartan (18.3 ± 14.3 mg/day). Mean serum potassium was increased significantly (P < 0.05) in patients treated with losartan (0.9 ± 2.8) as compared to patients treated with cilnidipine. A total of 19 ADRs were observed in both groups and out of these, 36.8% ADRs were caused by cilnidipine and 63.2% ADRs by losartan. Conclusion: Cilnidipine is equally effective as losartan in reducing blood pressure in hypertensive patients with type 2 DM. However, cilnidipine is more effective in the prevention of albuminuria and better tolerated by patients as compared with losartan.
INTRODUCTION
Hypertension like diabetes mellitus is "a silent killer," with a global prevalence of more than one billion people estimated in 2013. [1] Both hypertension and diabetes mellitus frequently coexist. [2] Usually, at initial stage of hypertension, there are few symptoms such as occipital headache. [3] Hypertension, if untreated for long-term, can lead to catastrophic outcomes such as cerebrovascular accident, coronary artery disease, chronic renal failure, and congestive heart failure. [4] There is frequently coexistence of hypertension and diabetes mellitus in patients and both accentuate the development of process of renal failure. [5] Renin angiotensin aldosterone system and over activity of sympathetic system play a crucial part in the evolution of heart failure and renal failure in hypertensive and diabetic patients, and merely control of mean arterial blood pressure and blood glucose is not sufficient in these patients.
vasodilation, inhibits the release of aldosterone, and blocks vascular and cardiac hypertrophy and remodeling action of AT 2 . [8] [9] [10] ARBs are used as primary antihypertensive agent in hypertensive-diabetic patients, as they slow the progression of diabetic nephropathy. [11] However, ARBs can produce adverse effects such as hyperkalemia, hypotension, angioedema, dry cough, and renal failure (in case of bilateral renal artery stenosis). [4] Cilnidipine, a novel dihydropyridine calcium channel blocker (CCB), inhibits the L-type and the N-type calcium channel. The N-type calcium channel is abundantly expressed in peripheral sympathetic nerve endings. Hence, cilnidipine reduces excessive release of catecholamine and suppresses reflective tachycardia compared with amlodipine (a L type CCB) in hypertensive patients. [12] [13] [14] In addition, a recent study showed that the L-type CCBs dilate the afferent, but not the efferent, arterioles of glomeruli; whereas cilnidipine dilates both the afferent and efferent arterioles, and prevents proteinuria. [15] Cilnidipine was shown to have a superior effect to amlodipine in preventing the progression of proteinuria in hypertensive patients. Among the available antihypertensive agents, both cilnidipine and losartan seem to have renoprotective effects However, there are no comparative data on the renoprotective effects of cilnidipine and losartan in hypertensive patients with noninsulin-dependent diabetes mellitus (NIDDM). The aim of the present study was to compare the efficacy and safety of cilnidipine and losartan in hypertensive patients with NIDDM.
MATERIALS AND METHODS
This was an observational, continuous, prospective, single center study conducted at the department of medicine of a tertiary care hospital in western part of India. This study was approved by Institutional Ethic Committee. Patients, who were recently diagnosed with essential hypertension and type 2 diabetes mellitus (type 2 DM), of either gender, 18 years or older and willing to participate in the study and gave written informed consent, treated with either tablet cilnidipine (10 mg/day) or tablet losartan (50 mg/ day) were enrolled into study from June 5, 2014 to May 31, 2015. Patients with severe renal or hepatic disease, overt cardiovascular disease, malignancy, and who had been treated with other antihypertensive drugs were excluded from study. Patients were randomized into two groups. First group received tablet cilnidipine 10 mg once a day for 24 weeks and second group received tablet losartan 50 mg once a day for 24 weeks. Demographic details and details of clinical examination, laboratory investigation, and drug treatment were recorded in a pretested case record form (CRF). Patients were followed up monthly for 24 weeks and observed for clinical improvement, changes in laboratory parameters such as serum potassium and albuminuria, and adverse drug reactions (ADRs). To evaluate the effect of cilnidipine and losartan on serum potassium and their renoprotective effect (by observing urinary albumin) in patients treated by these drugs, serum potassium and albuminuria were included into CRF. Data were recorded in Microsoft Excel Worksheet and analyzed using Fisher's exact test, repeated measure ANOVA, paired t-test, and unpaired t-test with the help of GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA 92037 USA). P < 0.05 was considered as statistically significant.
RESULTS

Baseline characteristics
Out of 122 patients, 78 (63.9) were men and 44 (36.1%) were women. Of these, 63 were treated with cilnidipine and 59 with losartan. Four patients were lost to follow-up in both groups. Hence, at the end of 24 weeks, 59 patients were treated with cilnidipine and 55 patients were treated with losartan [ Table 1 ].
Clinical assessment
A significant improvement (P < 0.01) in headache and dizziness was observed in patients treated with cilnidipine and losartan at 12 weeks. All patients were symptom-free at 24 weeks in both treatment groups [ Table 2 ]. In both treatment groups, mean systolic and diastolic blood pressure (mm of Hg) were significantly (P < 0.05) decreased by 12 weeks and 24 weeks [ Table 3 ], respectively, as compared to baseline.
Laboratorial assessment
A significant (P < 0.001) improvement in mean serum potassium and urinary albumin was observed in patients treated with cilnidipine at 24 weeks as compared to baseline [ Table 4 ]. By 24 weeks, in patients treated with losartan, there was significant (P < 0.01) reduction in urinary albuminuria; however, mean potassium level was increased significantly (P < 0.05). Values are absolute number and mean±SEM. NIDDM = Noninsulin dependent diabetes mellitus, SEM = Standard error of mean
Comparison between cilnidipine-and losartan-treated groups
There was a significant (P < 0.005) increase in mean serum potassium in patients treated with losartan at the end of the study as compared with cilnidipine-treated patients, which showed no significant change in potassium level in patients. By 24 weeks, there was a significant (P < 0.005) improvement in mean urinary albumin in patients treated with cilnidipine and losartan; however, mean decrease in urinary albumin was higher in patients treated with cilnidipine at the end of treatment [ Table 5 , Figures 1 and 2 ].
Adverse drug reactions
A total of 19 ADRs were observed in 114 patients during the study period. Out of these 19 ADRs, 7 were observed into patients treated with cilnidipine and 12 were into patients treated with losartan.
In patients treated with cilnidipine, the most common ADR was headache, (04) followed by dizziness (02). Most common ADRs observed in losartan-treated group were dizziness (04) and headache (03), followed by rashes (02) and hyperkalemia (02). ADRs were categorized as mild based on modified Hartwig and Siegel scale [ Table 6 ]. None of the ADR required withdrawal of causal drug. Majority of ADRs (19) were possibly related to the drug WHO-UMC scale except for dry cough and hyperkalemia in patients treated with losartan, which was probable in nature [ Table 6 ].
DISCUSSION
Essential hypertension and type 2 DM very commonly coexist and lead to the progression of diabetic nephropathy and cardiovascular disease. [6] Many clinical trials have recommended that the use of ARBs such as losartan slows the progression of diabetic nephropathy and it is commonly used as an antihypertensive drug in patients with essential hypertension with type 2 DM, [6, 7] although the use of ARBs alone for this purpose is not enough and is often prescribed with hydrochlorothiazide. Losartan frequently causes hyperkalemia, dry cough, rashes, and rarely angioedema-like severe ADRs in patients. [7, 8] Contrary to this, some studies have suggested that losartan and other ARBs are not efficacious to prevent the development of macroalbuminuria (≥300 mg/day urinary albumin) in hypertensive patients with type 2 DM having microalbuminuria (≤30-300 mg/day urinary albumin). [2, 3] However, cilnidipine, a third generation dihydropyridine, CCB is vasoselective and is a dual blocker of L-type and N-type calcium channels. L-type calcium channel blockade produce vasodilation of peripheral resistance vessels. Inhibition of neuronal N-type calcium channels disrupts sympathetic nervous outflow, lowering plasma catecholamine levels, and produces vasodilation of both pre-and post-capillary resistance vessels, reducing capillary hypertension and consequent hyperfiltration of fluid into the interstitium. [9, 10, 15] These dual mechanisms of cilnidipine explain both the low incidence of ankle edema and antihypertensive action without the reflex tachycardia. Cilnidipine effectively prevents the development of diabetic nephropathy and cardiovascular diseases in hypertensive patients with type 2 DM. [10, 11, 15] Our study showed the treatment outcomes of total 114 patients of hypertension with type 2 DM treated with cilnidipine and losartan for 24 weeks. At the end of 24 weeks, all patients had significant clinical improvement and normalization of laboratory parameters. Mean age of patients in both cilnidipine-and losartan-treated groups was 49.5 ± 14.6 years and 47.4 ± 8.3 years, respectively, which was lower than the mean age observed in a study conducted by Nishida et al., [14] in which mean age for ARBs was 61.7 years and for CCBs 66.8 years.
There were more men (63.9%) than women (36.1%) in our study. Similar observation was observed in a study carried out by Abe et al. [15] In our study, headache and dizziness were the most common presenting symptoms. Headache was because of an increased mean arterial blood pressure and severe hypertension. Similar findings had been reported in studies conducted by Nishida et al. [14] Serum potassium and urinary albumin were used to determine the effect of cilnidipine and losartan on potassium homeostasis and in the prevention of albuminuria.
Cilnidipine and losartan treatment resulted in a significant improvement in headache and dizziness at 12 weeks and all patients were symptom-free at the end of 6 months treatment with cilnidipine and losartan. Our observations are similar to the studies conducted by Nishida et al. [14] and Abe et al. [15] Treatment with cilnidipine and losartan decreases blood pressure and improves the signs and symptoms of essential hypertension.
A parallel improvement in laboratory parameters was noted in the present study. However, a significant increase in serum potassium was observed in patients treated with losartan as compared with cilnidipine. This observation suggested that losartan tends to increase serum potassium as compared to cilnidipine, which has no significant effect on serum potassium. Similar results were observed in studies conducted by Nishida et al., [14] Kurnik et al., [16] and Formica et al. [17] There was a significant (P < 0.005) improvement in albuminuria in patients treated with cilnidipine and losartan in our study, and such observations have been observed in studies carried out by Nishida et al. [14] Abe et al., [15] and Formica et al. [17] Although the mean age of patients in the study done by Nishida et al. [14] was higher, compared with the mean age of patients treated with cilnidipine and losartan in the present study, in both these studies, newly diagnosed hypertensive patients with type 2 DM were enrolled. However, in the present study, reduction in urinary albumin in patients treated with cilnidipine was more than in patients treated with losartan. This may be due to dual blockade of cilnidipine on L-type and N type of calcium channels which produces vasodilation of both pre -and post-capillary resistance vessels, reducing capillary hypertension and consequent hyperfiltration of fluid into the interstitium. In addition to this, cilnidipine decreases plasma AT 2 and aldosterone level. Losartan is a selective antagonist of AT 1 receptor and does not completely block the effect of AT 2 , which continues to produce albuminuria, especially in patients of NIDDM with hypertension. Similar results were observed in studies conducted by Kurnik et al. [16] and Formica et al. [17] In the present study, ADRs were more common in patients receiving losartan (63.2%) as compared with patients receiving cilnidipine (36.8%). Headache (57.1%) and dizziness (33.3%) were the most common observed ADRs in cilnidipine-and losartan-treated patients, respectively. ADRs such as peripheral edema and palpitation, which are commonly observed during treatment with amlodipine (a dihydropyridine CCB), were not observed in patients treated with cilnidipine during the present study. This may be attributed to dual blockage of both L-and N-type of calcium channels by cilnidipine. However, in patients treated with losartan, two cases of hyperkalemia and one case of dry cough were observed in our study. Similar observations were observed during the study conducted by Nishida et al. [14] All 19 ADRs observed in the present study were mild in severity (modified Hartwig and Siegel scale) and none of the ADR required withdrawal of patients from the study. All 19 ADRs were possible in nature except hyperkalemia and dry cough, which were probable in nature according to the WHO-UMC scale.
Limitations of the study
The study duration was of 6 months only and number of patients in both cilnidipine and losartan treated group is small. It was a nonrandomized, observational study. Considering the open-label design of the study, further large scale studies with controlled situation and blinding techniques are recommended to substantiate our observations. Despite these limitations, we believe that the data generated in our study lead to certain important conclusions.
CONCLUSION
Both cilnidipine and losartan are efficacious and safe in patients with essential hypertension and type 2 DM. However, cilnidipine is more efficacious in the prevention of albuminuria in hypertensive patients with type 2 DM and does not cause potassium imbalance. Losartan is associated with more ADRs such as hyperkalemia, dizziness, and dry cough.
